Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Roy M Fleischmann

Showing results (11-20 of 66) with videos related to

Pageof 7
Sort By:
Arthritis & Rheumatology (Hoboken, N.J.)|November 12, 2014
A randomized, double-blind, placebo-controlled, twelve-week, dose-ranging study of decernotinib, an oral selective JAK-3 inhibitor, as monotherapy in patients with active rheumatoid arthritisRoy M Fleischmann, Nemanja S Damjanov, Alan J Kivitz, et al.
The Journal of Rheumatology|August 16, 2015
Longterm Safety of Rituximab: Final Report of the Rheumatoid Arthritis Global Clinical Trial Program over 11 YearsRonald F van Vollenhoven, Roy M Fleischmann, Daniel E Furst, et al.
Clinical Therapeutics|November 19, 2008
Pharmacokinetic and pharmacodynamic properties of TRU-015, a CD20-directed small modular immunopharmaceutical protein therapeutic, in patients with rheumatoid arthritis: a Phase I, open-label, dose-escalation clinical studyDaniel J Burge, Stephen A Bookbinder, Alan J Kivitz, et al.
RMD Open|March 4, 2017
DAS28-CRP and DAS28-ESR cut-offs for high disease activity in rheumatoid arthritis are not interchangeableRoy M Fleischmann, Désirée van der Heijde, Philip V Gardiner, et al.
The Journal of Rheumatology|March 5, 2013
Evaluation of serum biomarkers associated with radiographic progression in methotrexate-naive rheumatoid arthritis patients treated with methotrexate or golimumabCarrie Wagner, Dion Chen, Hongtao Fan, et al.
Arthritis Research & Therapy|September 26, 2021
Long-term efficacy, safety, and immunogenicity of the adalimumab biosimilar, PF-06410293, in patients with rheumatoid arthritis after switching from reference adalimumab (Humira®) or continuing biosimilar therapy: week 52-92 data from a randomized, double-blind, phase 3 trialRoy M Fleischmann, Daniel F Alvarez, Amy E Bock, et al.
RMD Open|April 22, 2021
Randomised study of PF-06410293, an adalimumab (ADL) biosimilar, compared with reference ADL for the treatment of active rheumatoid arthritis: results from weeks 26-52, including a treatment switch from reference ADL to PF-06410293Roy M Fleischmann, Daniel F Alvarez, Amy E Bock, et al.
Rheumatology and Therapy|March 19, 2022
Usability Study of PF-06410293, an Adalimumab Biosimilar, by Prefilled Pen: Open-Label, Single-Arm, Sub-Study of a Phase 3 Trial in Patients with Rheumatoid ArthritisRoy M Fleischmann, Amy E Bock, Wuyan Zhang, et al.
The Journal of Rheumatology|August 4, 2004
Etanercept (Enbrel) in patients with rheumatoid arthritis with recent onset versus established disease: improvement in disabilityScott W Baumgartner, Roy M Fleischmann, Larry W Moreland, et al.
Clinical and Experimental Rheumatology|November 18, 2015
Efficacy and safety of tofacitinib in US and non-US rheumatoid arthritis patients: pooled analyses of phase II and IIIStanley B Cohen, Andrew Koenig, Lisy Wang, et al.
Pageof 7

Showing results (11-20 of 66) with videos related to

Sort By:
Pageof 7
Arthritis & Rheumatology (Hoboken, N.J.)|November 12, 2014
A randomized, double-blind, placebo-controlled, twelve-week, dose-ranging study of decernotinib, an oral selective JAK-3 inhibitor, as monotherapy in patients with active rheumatoid arthritisRoy M Fleischmann, Nemanja S Damjanov, Alan J Kivitz, et al.
The Journal of Rheumatology|August 16, 2015
Longterm Safety of Rituximab: Final Report of the Rheumatoid Arthritis Global Clinical Trial Program over 11 YearsRonald F van Vollenhoven, Roy M Fleischmann, Daniel E Furst, et al.
Clinical Therapeutics|November 19, 2008
Pharmacokinetic and pharmacodynamic properties of TRU-015, a CD20-directed small modular immunopharmaceutical protein therapeutic, in patients with rheumatoid arthritis: a Phase I, open-label, dose-escalation clinical studyDaniel J Burge, Stephen A Bookbinder, Alan J Kivitz, et al.
RMD Open|March 4, 2017
DAS28-CRP and DAS28-ESR cut-offs for high disease activity in rheumatoid arthritis are not interchangeableRoy M Fleischmann, Désirée van der Heijde, Philip V Gardiner, et al.
The Journal of Rheumatology|March 5, 2013
Evaluation of serum biomarkers associated with radiographic progression in methotrexate-naive rheumatoid arthritis patients treated with methotrexate or golimumabCarrie Wagner, Dion Chen, Hongtao Fan, et al.
Arthritis Research & Therapy|September 26, 2021
Long-term efficacy, safety, and immunogenicity of the adalimumab biosimilar, PF-06410293, in patients with rheumatoid arthritis after switching from reference adalimumab (Humira®) or continuing biosimilar therapy: week 52-92 data from a randomized, double-blind, phase 3 trialRoy M Fleischmann, Daniel F Alvarez, Amy E Bock, et al.
RMD Open|April 22, 2021
Randomised study of PF-06410293, an adalimumab (ADL) biosimilar, compared with reference ADL for the treatment of active rheumatoid arthritis: results from weeks 26-52, including a treatment switch from reference ADL to PF-06410293Roy M Fleischmann, Daniel F Alvarez, Amy E Bock, et al.
Rheumatology and Therapy|March 19, 2022
Usability Study of PF-06410293, an Adalimumab Biosimilar, by Prefilled Pen: Open-Label, Single-Arm, Sub-Study of a Phase 3 Trial in Patients with Rheumatoid ArthritisRoy M Fleischmann, Amy E Bock, Wuyan Zhang, et al.
The Journal of Rheumatology|August 4, 2004
Etanercept (Enbrel) in patients with rheumatoid arthritis with recent onset versus established disease: improvement in disabilityScott W Baumgartner, Roy M Fleischmann, Larry W Moreland, et al.
Clinical and Experimental Rheumatology|November 18, 2015
Efficacy and safety of tofacitinib in US and non-US rheumatoid arthritis patients: pooled analyses of phase II and IIIStanley B Cohen, Andrew Koenig, Lisy Wang, et al.
Pageof 7